Injectable platelet-rich fibrin

Phase 3

Injectable platelet-rich fibrin is one of 28 therapeutic programs targeting Temporomandibular Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Temporomandibular DisorderEnrolling by invitation

Bony DefectsNot yet recruiting

PeriodontitisRecruiting

Temporomandibular DisorderPreclinical

Enrolling by invitation

Bony DefectsPreclinical

Not yet recruiting

PeriodontitisPhase 3

Recruiting

Competition

Competitive Landscape

34 competitors in Periodontitis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

4 2

Neoral

Voltaren

Crestor

Biaxin

Epidiolex

Minocin

1 8

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

1 9

Floxin

WWim Janssens

Approved

1 10

Glucophage

EMD Serono

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Periodontitis

NCT07707063

Q4 2027

PreclinicalNot yet recruiting

Bony Defects

NCT07791238

Clinical

Trials by Indication[1]

Bony Defects1 trial

Impact of I-PRF With or Without Chlorhexidine on Minimally Invasive Non-Surgical Periodontal Therapy in Stage III Periodontitis: A Randomized Clinical Trial

Not yet recruiting·CCairo University·Preclinical·NCT07791238·63 enrolled

Gingival Overgrowth1 trial

Clinical and Biochemical Evaluation of the Effect of Injectable Platelet-rich Fibrin Applied to the Operation Site After Gingivectomy

Completed·ŞŞeyma Çardakçı·Preclinical·NCT07785349·31 enrolled

Periodontitis1 trial

Clinical Efficacy of I-PRF, Povidone-Iodine and Laser as Adjuncts to Non-surgical Periodontal Treatment in Smokers and Non-Smokers Periodontitis Patients : A Split Mouth Randomized Clinical Trial

Recruiting·MMilitary Hospital of Tunis·Approved·NCT07707063·50 enrolled

Temporomandibular Disorder1 trial

Assessment of the Effectiveness of Intra-articular Injectable Platelet-rich Fibrin (iPRF) Injections in the Management of Mild and Moderate Degeneration of the Temporomandibular Joints

Enrolling by invitation·WWroclaw Medical University·Preclinical·NCT05214924·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Injectable platelet-rich fibrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Injectable platelet-rich fibrin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wroclaw Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: WWroclaw Medical University

Injectable platelet-rich fibrin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Bony Defects1 trial

Gingival Overgrowth1 trial

Periodontitis1 trial

Temporomandibular Disorder1 trial

References

Drug Info

Quick Facts

Related News